Goss Alastair, Bartold Mark, Sambrook Paul, Hawker Peter
Oral & Maxillofacial Surgery Unit, The University of Adelaide, Adelaide, Australia.
J Oral Maxillofac Surg. 2010 Feb;68(2):337-43. doi: 10.1016/j.joms.2009.09.037.
To determine the number of bisphosphonate-associated cases of dental implant failure in South Australia.
All general and specialist dentists who place dental implants in South Australia were contacted and asked to provide information on the total number of implants placed over the decade to December 2007. Cases of bisphosphonate-associated implant failure were identified.
All 46 practitioners involved in implant placement and the management of bisphosphonate-associated osteonecrosis of the jaws in South Australia were identified. Approximately 28,000 implants had been placed in 16,000 patients. We identified 7 cases of oral bisphosphonate-associated implant failure, with 3 cases of failure of osseointegration and 4 cases of successful implants losing integration after being placed on oral bisphosphonates. There were 5 women and 2 men, and the mean age was 65.7 years (range, 49-75 years). Only 1 was medically compromised, with steroids and diabetes. No cases of implant failure in intravenous bisphosphonate cases were identified. On the basis of the assumption that 5% of the patients were taking an oral bisphosphonate, 1 in 114 (0.89%) had implant failure.
In patients taking oral bisphosphonates, a failure to integrate or subsequent loss of integration may occur when oral bisphosphonates are started after successful implant placement. The rate of failure is low, at less than 1%.
确定南澳大利亚州双膦酸盐相关的牙种植失败病例数。
联系了南澳大利亚州所有植入牙种植体的普通牙医和专科牙医，要求他们提供截至2007年12月的十年间植入的种植体总数信息。确定双膦酸盐相关的种植失败病例。
确定了南澳大利亚州所有46名参与种植体植入及双膦酸盐相关颌骨坏死管理的从业者。约16000名患者共植入了约28000颗种植体。我们确定了7例口服双膦酸盐相关的种植失败病例，其中3例为骨结合失败，4例为成功植入的种植体在开始口服双膦酸盐后失去结合。患者中有5名女性和2名男性，平均年龄为65.7岁（范围49 - 75岁）。仅1例患者有类固醇和糖尿病等医学问题。未发现静脉注射双膦酸盐病例的种植失败情况。基于5%的患者服用口服双膦酸盐这一假设，114名患者中有1名（0.89%）发生种植失败。
在服用口服双膦酸盐的患者中，成功植入种植体后开始服用口服双膦酸盐时，可能会出现无法结合或随后失去结合的情况。失败率较低，低于1%。
